Schippers, M., Post, E., Eichhorn, I., Langeland, J., Beljaars, L., Malo, M. S., Hodin, R. A., Popov, Y., Schuppan, D., & Poelstra, K. (2020). Phosphate Groups in the Lipid A Moiety Determine the Effects of LPS on Hepatic Stellate Cells: A Role for LPS-Dephosphorylating Activity in Liver Fibrosis. Cells, 9(12), [2708]. https://doi.org/10.3390/cells9122708

Adhyatmika, A., Beljaars, L., Putri, K. S. S., Habibie, H., Boorsma, C. E., Reker-Smit, C., Luangmonkong, T., Guney, B., Haak, A., Mangnus, K. A., Post, E., Poelstra, K., Ravnskjaer, K., Olinga, P., & Melgert, B. N. (2020). Osteoprotegerin Is more than a Possible Serum Marker in Liver Fibrosis: A Study into Its Function in Human and Murine Liver. Pharmaceutics, 12(5), [471]. https://doi.org/10.3390/pharmaceutics12050471

Poelstra, K. (2020). Innovative Nanotechnological Formulations to Reach the Hepatic Stellate Cell. Current Tissue Microenvironment Reports, 1, 13-22. https://doi.org/10.1007/s43152-020-00004-x

van Dijk, F., Hazelhoff, C. M., Post, E., Prins, G. G. H., Rombouts, K., Poelstra, K., Olinga, P., & Beljaars, L. (2020). Design of a Gene Panel to Expose the Versatile Role of Hepatic Stellate Cells in Human Liver Fibrosis. Pharmaceutics, 12(3), [278]. https://doi.org/10.3390/pharmaceutics12030278

van Dijk, F., Teekamp, N., Post, E., Schuppan, D., Kim, Y. O., Zuidema, J., Steendam, R., Klose, M. H. M., Meier-Menches, S. M., Casini, A., Horvatovich, P. L., Sijbrandi, N. J., Frijlink, H. W., Hinrichs, W. L. J., Poelstra, K., Beljaars, L., & Olinga, P. (2019). The antifibrotic potential of a sustained release formulation of a PDGF beta-receptor targeted rho kinase inhibitor. Journal of Controlled Release, 296, 250-257. https://doi.org/10.1016/j.jconrel.2018.12.039

Klein, S., Frohn, F., Magdaleno, F., Reker-Smit, C., Schierwagen, R., Schierwagen, I., Uschner, F. E., van Dijk, F., Fürst, D. O., Djudjaj, S., Boor, P., Poelstra, K., Beljaars, L., & Trebicka, J. (2019). Rho-kinase inhibitor coupled to peptide-modified albumin carrier reduces portal pressure and increases renal perfusion in cirrhotic rats. Scientific Reports, 9(1), 2256. https://doi.org/10.1038/s41598-019-38678-5

Deshmukh, M., Nakagawa, S., Higashi, T., Vincek, A., Venkatesh, A., Ruiz de Galarreta, M., Koh, A. P., Goossens, N., Hirschfield, H., Bian, C. B., Fujiwara, N., Ono, A., Hoshida, H., El-Abtah, M., Ahmad, N. B., Lujambio, A., Sanchez, R., Fuchs, B. C., Poelstra, K., ... Hoshida, Y. (2018). Cell type-specific pharmacological kinase inhibition for cancer chemoprevention. Nanomedicine-Nanotechnology biology and medicine, 14(2), 317-325. https://doi.org/10.1016/j.nano.2017.11.004

van Dijk, F., Teekamp, N., Beljaars, L., Post, E., Zuidema, J., Steendam, R., Kim, Y. O., Frijlink, H. W., Schuppand, D., Poelstra, K., Hinrichs, W. L. J., & Olinga, P. (2018). Pharmacokinetics of a sustained release formulation of PDGFβ-receptor directed carrier proteins to target the fibrotic liver. Journal of Controlled Release, 269, 258-265. https://doi.org/10.1016/j.jconrel.2017.11.029

Teekamp, N., Van Dijk, F., Broesder, A., Evers, M., Zuidema, J., Steendam, R., Post, E., Hillebrands, J. L., Frijlink, H. W., Poelstra, K., Beljaars, L., Olinga, P., & Hinrichs, W. L. J. (2017). Polymeric microspheres for the sustained release of a protein-based drug carrier targeting the PDGFβ-receptor in the fibrotic kidney. International Journal of Pharmaceutics, 534(1-2), 229-236. https://doi.org/10.1016/j.ijpharm.2017.09.072

Schippers, M., Beljaars, L., Post, E., Lotersztajn, S., Reker-Smit, C., Han, B., Llancao, P. A., Schmidt, M., & Poelstra, K. (2017). Upregulation of Epac-1 in Hepatic Stellate Cells by Prostaglandin E-2 in Liver Fibrosis Is Associated with Reduced Fibrogenesiss. Journal of Pharmacology and Experimental Therapeutics, 363(2), 126-135. https://doi.org/10.1124/jpet.117.241646

Magdaleno, F., Klein, S., Frohn, F., Reker-Smit, C., Uschner, F. E., Schierwagen, R., Poelstra, K., Beljaars, L., & Trebicka, J. (2017). Rho-kinase inhibitor coupled with peptide-modified albumin carrier reduces fibrogenesis and portal pressure in cirrhotic rats without systemic effects. Hepatology, 66(1 (Suppl.)), 142A-142A.

van Dijk, F., Teekamp, N., Beljaars, L., Post, E., Kim, Y. O., Frijlink, E., Hinrichs, W., Schuppan, D., Poelstra, K., & Olinga, P. (2017). Therapeutic proteins in the treatment of liver fibrosis: The antifibrotic potential of a sustained release formulation for a PDGF beta-receptor targeted rho-kinase inhibitor. Hepatology, 66, 217A.

Beljaars, L., Daliri, S., Dijkhuizen, C., Poelstra, K., & Gosens, R. (2017). WNT-5A regulates TGFβ-related activities in liver fibrosis. American Journal of Physiology-Gastrointestinal and Liver Physiology, 312(3), G219-G227. https://doi.org/10.1152/ajpgi.00160.2016

Van Dijk, F., Teekamp, N., Beljaars, L., Post, E., Schuppan, D., Kim, Y. O., Poelstra, K., Frijlink, E., Hinrichs, W., & Olinga, P. (2017). Towards clinical use of targeted therapies for liver fibrosis: development of a sustained release formulation for therapeutic proteins. Journal of Hepatology, 66(1), S44-S44.

Poosti, F., Bansal, R., Yazdani, S., Prakash, J., Beljaars, L., van den Born, J., de Borst, M. H., van Goor, H., Hillebrands, J-L., & Poelstra, K. (2016). Interferon gamma peptidomimetic targeted to interstitial myofibroblasts attenuates renal fibrosis after unilateral ureteral obstruction in mice. Oncotarget, 7(34), 54240-54252. https://doi.org/10.18632/oncotarget.11095

Draijer, C., Boorsma, C. E., Reker-Smit, C., Post, E., Poelstra, K., & Melgert, B. N. (2016). PGE(2)-treated macrophages inhibit development of allergic lung inflammation in mice. Journal of Leukocyte Biology, 100(1), 95-102. https://doi.org/10.1189/jlb.3MAB1115-505R

Poelstra, K. (2016). Liver fibrosis in 2015: Crucial steps towards an effective treatment. Nature Reviews Gastroenterology & Hepatology, 13(2), 67-68. https://doi.org/10.1038/nrgastro.2015.224

Draijer, C., Boorsma, C. E., Reker-Smit, C., Post, E., Poelstra, K., & Melgert, B. N. (2016). PGE2-treated macrophages inhibit development of allergic lung inflammation in mice. Journal of Leukocyte Biology, 100(1), 95-102. https://doi.org/10.1189/jlb.3MAB1115-505R

Draijer, C., Boorsma, C. E., Reker-Smit, C., Post, E., Poelstra, K., & Melgert, B. N. (2016). PGE2-treated macrophages inhibit development of allergic lung inflammation in mice. American Journal of Respiratory and Critical Care Medicine, 193.

Poosti, F., Pham, B., Oosterhuis, D., Poelstra, K., van Goor, H., Olinga, P., & Hillebrands, J-L. (2015). Precision-cut kidney slices (PCKS) to study development of renal fibrosis and efficacy of drug targeting ex vivo. Disease models & mechanisms, 8(10), 1227-1236. https://doi.org/10.1242/dmm.020172

Poosti, F., Bansal, R., Yazdani, S., Prakash, J., Post, E., Klok, P., van den Born, J., de Borst, M. H., van Goor, H., Poelstra, K., & Hillebrands, J-L. (2015). Selective delivery of IFN-γ to renal interstitial myofibroblasts: a novel strategy for the treatment of renal fibrosis. The FASEB Journal, 29(3), 1029-1042. https://doi.org/10.1096/fj.14-258459

van Dijk, F., Olinga, P., Poelstra, K., & Beljaars, L. (2015). Targeted Therapies in Liver Fibrosis: Combining the Best Parts of Platelet-Derived Growth Factor BB and Interferon Gamma. Frontiers in Medicine, 2, [72]. https://doi.org/10.3389/fmed.2015.00072

Beljaars, L., Schippers, M., Reker-Smit, C., Martinez, F. O., Helming, L., Poelstra, K., & Melgert, B. N. (2014). Hepatic Localization of Macrophage Phenotypes during Fibrogenesis and Resolution of Fibrosis in Mice and Humans. Frontiers in Immunology, 5, [430]. https://doi.org/10.3389/fimmu.2014.00430

Mahajan, V., Hartimath, S., Comley, R., Poelstra, K., Reker-Smit, C., Kamps, J., Sijbesma, J., Stephan-Gueldner, M., Dierckx, R., & de Vries, E. (2014). Non-invasive imaging of Kupffer cell status using radiolabelled mannosylated albumin. Journal of Nuclear Medicine, 55(Supplement 1).

Arabpour, M., Poelstra, K., Helfrich, W., Bremer, E., & Haisma, H. J. (2014). Targeted Elimination of Activated Hepatic Stellate Cells by Anti-EGF-Receptor scFv-sTRAIL Fusion Protein. Molecular Therapy, 22(suppl. 1), S121-S121.

Bansal, R., Prakash, J., De Ruiter, M., & Poelstra, K. (2014). Interferon gamma peptidomimetic targeted to hepatic stellate cells ameliorates acute and chronic liver fibrosis in vivo. Journal of Controlled Release, 179, 18-24. https://doi.org/10.1016/j.jconrel.2014.01.022

Mahajan, V., Hartimath, S., Comley, R., Stefan-Gueldner, M., Roth, A., Poelstra, K., Reker-Smit, C., Kamps, J., Dierckx, R., & de Vries, E. (2014). Non-invasive imaging of kupffer cell status using radiolabelled mannosylated albumin. Journal of Hepatology, 60(1, Suppl.), S180-S181. https://doi.org/10.1016/S0168-8278(14)60503-1

Poelstra, K. (2014). New Highlights for Relaxin. Hepatology, 59(4), 1223-1224. https://doi.org/10.1002/hep.26713

Bansal, R., Prakash, J., De Ruiter, M., & Poelstra, K. (2014). Targeted Recombinant Fusion Proteins of IFN gamma and Mimetic IFN gamma with PDGF beta R Bicyclic Peptide Inhibits Liver Fibrogenesis In Vivo. PLoS ONE, 9(2), [e89878]. https://doi.org/10.1371/journal.pone.0089878

Beljaars, L., Boorsma, C. E., Guney, B., Poelstra, K., & Melgert, B. N. (2014). A new communication system regulating extracellular matrix in liver fibrosis: RANK/RANKL/OPG. Hepatology, 60(Supplement 1), 584A-584A. https://doi.org/10.1002/hep.27412

Arabpour, M., Poelstra, K., Helfrich, W., Bremer, E., & Haisma, H. J. (2014). Targeted elimination of activated hepatic stellate cells by an anti-epidermal growth factor-receptor single chain fragment variable antibody-tumor necrosis factor-related apoptosis-inducing ligand (scFv425-sTRAIL). Journal of gene medicine, 16(9-10), 281-290. https://doi.org/10.1002/jgm.2776

Poelstra, K., Beljaars, L., & Melgert, B. N. (2013). Cell-specific delivery of biologicals: Problems, pitfalls and possibilities of antifibrotic compounds in the liver. Drug Discovery Today, 18(23-24), 1237-1242. https://doi.org/10.1016/j.drudis.2013.05.013

Beljaars, L., Daliri, S., Dijkhuizen, C., Poelstra, K., & Gosens, R. (2013). Exploring the role of WNT-5A in liver fibrogenesis. Hepatology, 58(SI), 589A. [805].

Schippers, M., Post, E., Cetintas, A., Reker-Smit, C., Malo, M. S., Hodin, R. A., Millan, J. L., Beljaars, L., & Poelstra, K. (2013). Intrahepatic alkaline phosphatase attenuates LPS-mediated effects during liver fibrosis. Hepatology, 58(SI), 579A.

van Beuge, M. M., Prakash, J., Lacombe, M., Post, E., Reker-Smit, C., Beljaars, L., & Poelstra, K. (2013). Enhanced Effectivity of an ALK5-Inhibitor after Cell-Specific Delivery to Hepatic Stellate Cells in Mice with Liver Injury. PLoS ONE, 8(2), [e56442]. https://doi.org/10.1371/journal.pone.0056442

Klein, S., Van Beuge, M. M., Granzow, M., Beljaars, L., Schierwagen, R., Kilic, S., Heidari, I., Huss, S., Sauerbruch, T., Poelstra, K., & Trebicka, J. (2012). HSC-specific inhibition of Rho-kinase reduces portal pressure in cirrhotic rats without major systemic effects. Journal of Hepatology, 57(6), 1220-1227. https://doi.org/10.1016/j.jhep.2012.07.033

Bansal, R., Tomar, T., Ostman, A., Poelstra, K., & Prakash, J. (2012). Selective Targeting of Interferon gamma to Stromal Fibroblasts and Pericytes as a Novel Therapeutic Approach to Inhibit Angiogenesis and Tumor Growth. Molecular cancer therapeutics, 11(11), 2419-2428. https://doi.org/10.1158/1535-7163.MCT-11-0758

Mattos Pinto, A., de Jager-Krikken, A., de Haan, M., Beljaars, L., & Poelstra, K. (2012). PEGylation of interleukin-10 improves the pharmacokinetic profile and enhances the antifibrotic effectivity in CCl4-induced fibrogenesis in mice. Journal of Controlled Release, 162(1), 84-91. https://doi.org/10.1016/j.jconrel.2012.05.041

Poelstra, K., Prakash, J., & Beljaars, L. (2012). Drug targeting to the diseased liver. Journal of Controlled Release, 161(2), 188-197. https://doi.org/10.1016/j.jconrel.2012.02.011

van Beuge, M. M., Poelstra, K., & Prakash, J. (2012). Specific delivery of kinase inhibitors in nonmalignant and malignant diseases. Expert Opinion on Drug Delivery, 9(1), 59-70. https://doi.org/10.1517/17425247.2012.638625

Klein, S., Granzow, M., Schierwagen, R., Kilic, S., Heidari, I., Huss, S., van Beuge, M., Sauerbruch, T., Poelstra, K., & Trebicka, J. (2012). Gezielte Rho-Kinase-Hemmung in Hepatischen Sternzellen als Therapie der portalen Hypertension bei der Leberzirrhose. Zeitschrift für Gastroenterologie, 50(08). https://doi.org/10.1055/s-0032-1323962

Klein, S., Granzow, M., Schierwagen, R., Huss, S., van Beuge, M., Poelstra, K., Sauerbruch, T., & Trebicka, J. (2012). HSC gezielte Hemmung der Rho-kinase senkt den Portaldruck mit geringen systemischen Nebenwirkungen. Zeitschrift für Gastroenterologie, 50(01). https://doi.org/10.1055/s-0031-1295752

Bansal, R., Post, E., Proost, J. H., de Jager-Krikken, A., Poelstra, K., & Prakash, J. (2011). PEGylation improves pharmacokinetic profile, liver uptake and efficacy of Interferon gamma in liver fibrosis. Journal of Controlled Release, 154(3), 233-240. https://doi.org/10.1016/j.jconrel.2011.05.027

de Jong, E., Winkel, P., Poelstra, K., & Prakash, J. (2011). Anticancer Effects of 15d-Prostaglandin-J(2) in Wild-Type and Doxorubicin-Resistant Ovarian Cancer Cells: Novel Actions on SIRT1 and HDAC. PLoS ONE, 6(9), [25192]. https://doi.org/10.1371/journal.pone.0025192

Wisastra, R., Poelstra, K., Bischoff, R., Maarsingh, H., Haisma, H. J., & Dekker, F. J. (2011). Antibody-Free Detection of Protein Tyrosine Nitration in Tissue Sections. ChemBioChem, 12(13), 2016-2020. https://doi.org/10.1002/cbic.201100148

Poelstra, K., & Schuppan, D. (2011). Targeted therapy of liver fibrosis/cirrhosis and its complications. Journal of Hepatology, 55(3), 726-728.

Klein, S., Granzow, M., Gautsch, S., van Beuge, M., Poelstra, K., Sauerbruch, T., & Trebicka, J. (2011). HSC-gezielte Hemmung der Rho-kinase senkt den Portaldruck mit nur geringen systemischen Nebenwirkungen. Zeitschrift für Gastroenterologie, 49(08). https://doi.org/10.1055/s-0031-1285665

van Beuge, M. M., Prakash, J., Lacombe, M., Post, E., Reker-Smit, C., Beljaars, L., & Poelstra, K. (2011). Increased Liver Uptake and Reduced Hepatic Stellate Cell Activation with a Cell-Specific Conjugate of the Rho-kinase Inhibitor Y27632. Pharmaceutical Research, 28(8), 2045-2054. https://doi.org/10.1007/s11095-011-0430-9

Bansal, R., Prakash, J., Post, E., Beljaars, L., Schuppan, D., & Poelstra, K. (2011). Novel Engineered Targeted Interferon-gamma Blocks Hepatic Fibrogenesis in Mice. Hepatology, 54(2), 586-596. https://doi.org/10.1002/hep.24395

van Beuge, M. M., Prakash, J., Lacombe, M., Gosens, R., Post, E., Reker-Smit, C., Beljaars, L., & Poelstra, K. (2011). Reduction of Fibrogenesis by Selective Delivery of a Rho Kinase Inhibitor to Hepatic Stellate Cells in Mice. Journal of Pharmacology and Experimental Therapeutics, 337(3), 628-635. https://doi.org/10.1124/jpet.111.179143